Condition: High-grade Glioma · Medulloblastoma · Diffuse Intrinsic Pontine Glioma · Sponsor: Emory University
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.
This description comes directly from the study's public registry record.
Tobey MacDonald, MD · 404-727-1447 · aflacdevtreferral@choa.org
Amber Kaminski · aflacdevtreferral@choa.org
Always discuss trial participation with your own doctor first.
| Arthur M Blank Hospital | Atlanta, Georgia, United States | Recruiting |
| Children's Healthcare of Atlanta: Scottish Rite | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06624371